Becton, Dickinson and Company (BDX) - NYSE
  • Jan. 16, 2015, 7:16 AM
    • Thinly-traded nano cap Retractable Technologies (NYSEMKT:RVP) jumps 31% premarket after the U.S. District Court for the Eastern District of Texas rules against Becton, Dickinson and Company (NYSE:BDX) in its appeal of a September 2013 award of $113M to RVP, who accused BDX attempting to monopolize the safety syringe market.
    • The Court's final judgement states that BDX attempted to monopolize the safety syringe market and committed false advertising under the Lanham Act. It awards RVP $340,524,042 plus $11,722,823.20 for attorneys fees plus pre- and post-judgment interest and costs and injunctive relief consistent with prior court orders. All other motions not previously resolved are denied.
    | Jan. 16, 2015, 7:16 AM
  • Oct. 6, 2014, 9:16 AM
    | Oct. 6, 2014, 9:16 AM
  • Jan. 7, 2014, 9:58 AM
    • BofA upgrades Perrigo (PRGO +1.2%) to Buy from Neutral. RBC starts the shares as a Top Pick, with a $187 price target.
    • BofA upgrades Becton Dickinson (BDX +0.8%) to Neutral from Underperform.
    • RBC upgrades Johnson & Johnson (JNJ +1.6%) to Outperform from Sector Perform. Price target is $104.
    • Citi upgrades Varian Medical (VAR +1.6%) to Neutral from Sell.
    • Roth starts ANI Pharma (ANIP +9.5%) at Buy. Price target is $27.
    • RBC starts Teva (TEVA +0.1%) at Sector Perform. Price target is $39.
    • RBC starts AcelRx (ACRX +2.5%) at Outperform. Price target is $15.
    • RBC starts Mylan (MYL +2.3%) at Outperform. Price target is $50.
    • RBC starts Allergan (AGN +1.3%) at Outperform. Price target is $131.
    • RBC starts Impax Labs (IPXL +0.2%) at Sector Perform. Price target is $25.
    | Jan. 7, 2014, 9:58 AM | 3 Comments
  • Dec. 17, 2013, 8:30 AM
    • Biodel (BIOD) jumps 14% in premarket trading.
    • The company has inked a long-term supply deal with Becton, Dickinson (BDX) for exclusive rights to the BD Uniject SCF Disposable Auto-Disable Injection System.
    • BIOD will leverage the device to serve the "glucagon rescue treatment market by replacing antiquated, difficult, and cumbersome multi-part kits with simple, convenient, portable therapies."
    • In other words, the company is using the devices to deliver liquid glucagon for the treatment of hypoglycemia. (PR)
    | Dec. 17, 2013, 8:30 AM
  • Sep. 20, 2013, 9:01 AM
    • Make no mistake: It's a good day to be long Retractable Technologies (RVP).
    • After a protracted legal battle, a jury returned a favorable verdict Thursday in litigation against Becton, Dickinson (BDX).
    • RVP accused BDX of attempting to monopolize the safety syringe market.
    • RVP is awarded $113.5M in compensatory damages. (PR)
    • The market reaction: RVP +141% premarket
    | Sep. 20, 2013, 9:01 AM | 1 Comment
  • May 2, 2013, 12:07 PM

    Becton Dickinson (BDX +2.9%) trades up after a solid FQ2 earnings beat this morning. Net earnings fell 5.3% Y/Y however as a new medical-device tax overshadowed better revenue. Medical unit revenue rose 4% to $1.06B. Revenue at the diagnostics unit increased 4.6%, and bio-sciences revenue was up 0.6%. The medical-device maker also raised its FY13 earnings by $0.03 to a range of $5.72 to $5.75 a share and backed its revenue growth projection of 3.5% - 4%.

    | May 2, 2013, 12:07 PM
  • Feb. 5, 2013, 12:33 PM

    Becton Dickinson (BDX +2.8%) moves up after its FQ1 easily tops estimates. Net profit more than doubled on revenue growth across all segments, while margins widened to 52.9% from 50.8%. Sales in its U.S. markets grew by 3% Y/Y, and 4.3% internationally. Sales in its medical unit, the largest by revenue, rose 3.5%. For the current year, The company bumps up the bottom end of revenue guidance, now expecting revenue growth starting at 4% versus its prior view of 3.5%, and an EPS of between $5.69 and $5.72, up from its earlier view of $5.58 to $5.64.

    | Feb. 5, 2013, 12:33 PM
  • Nov. 7, 2012, 10:07 AM

    More on Becton Dickinson (BDX -3.8%) FQ4: net profit -3.6% to $289M, with earnings hurt by weak revenue at its biosciences and medical ops, pension settlement charges, and forex fluctuations. U.S. sales +1.2%, international -2.6%, but +7.1% excluding currency impact. Gross margin falls to 50.9% from 51.2%. Expects FY revenue growth of 2%-3% and EPS from continuing ops of $5.58-$5.64 vs consensus of +3% and $5.80.

    | Nov. 7, 2012, 10:07 AM
  • Feb. 7, 2012, 10:35 AM

    Becton Dickinson (BDX -3.6%) drifts lower after posting a lackluster FQ1 earnings report. Net profit fell 17% Y/Y on higher raw materials costs and expenses from recent acquisitions. The company also lowers its FY12 earnings forecast on flat revenue, reflecting the impact of a strengthening U.S. dollar. It now expects to earn between $5.60 - $5.70, below the Street view of $5.80.

    | Feb. 7, 2012, 10:35 AM
  • Feb. 7, 2012, 6:20 AM
    Becton Dickinson (BDX): FQ1 EPS of $1.21 beats by $0.04. Revenue of $1.88B (+2.5% Y/Y) in-line. Shares -3.7% premarket. (PR)
    | Feb. 7, 2012, 6:20 AM
  • Nov. 2, 2011, 9:00 AM

    Premarket gainers: HGG +15%. MELA +11%. GRMN +10%. MGIC +9%. MA +7%. JDSU +6%. AUO +5%. CHU +5%. EXEL +5%. RENN +5%. RDN +5%. NBG +4%. HAL +4%. AKS +4%. BAC +4%. LNG +4%. PCS +3%. MS +3%. FCX +3%. SIRI +3%. S +3%. C +3%. AA +3%.
    Losers: DMND -16%. OPEN -13%. VG -12%. HGSI -7%. BDX -6%. LYG -5%. CTSH -4%.

    | Nov. 2, 2011, 9:00 AM
Company Description
Becton, Dickinson & Co. is a global medical technology company. The company is engaged in the development, manufacture and sale of medical devices, instrument systems and reagents used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and... More
Sector: Healthcare
Industry: Medical Instruments & Supplies
Country: United States